TY - JOUR AU - Todoriko, L.D. AU - Pidverbetska, O.V. PY - 2021/06/29 Y2 - 2024/03/28 TI - Management of pulmonary tuberculosis on the background of intestinal malabsorption syndrome JF - Infusion & Chemotherapy JA - IC VL - IS - 2 SE - ORIGINAL STUDIES DO - 10.32902/2663-0338-2021-2-39-43 UR - https://infusion-chemotherapy.com/index.php/journal/article/view/208 SP - 39-43 AB - OBJECTIVE. To investigate the frequency of malabsorption in newly diagnosed sensitive pulmonary tuberculosis (TB) and to establish the effectiveness of treatment correction in these patients.MATERIALS AND METHODS. In the first stage of the study, 73 patients with new drug-susceptible TB underwent lactulose-mannitol test. Individuals with intestinal permeability index <3 were selected and divided into main group which received injectable forms of isoniazid, rifampicin, ethambutol and oral pyrazinamide and control group which received standard treatment orally.RESULTS. Bacterial excretion stopped in 88.2 % of patients in the main group and in only 61.5 % of patients in the control group. In 46.1 % of cases in the control group treatment failure was diagnosed. The frequency of positive radiological dynamics at the end of the intensive phase of treatment was 64.7 % in the main group versus 30.8 % in the control group. The total efficacy of treatment at the end of the main course of chemotherapy was 88.2 % in the main group against 53.9 % in the control group (p <0.05).CONCLUSIONS. Malabsorption, which requires correction of treatment, occurs in about one-fifth of patients with new TB. Usage of injectable anti-TB drugs in such patients increases the effectiveness of treatment by 34 % (p <0.05). ER -